Cell therapy newco GammaDelta launched

Immunotherapy newco GammaDelta Therapeutics Ltd. (London, U.K.) raised an undisclosed amount of seed funding from Abingworth. The start-up is developing gamma delta T cell therapies to treat cancer (see BioCentury Innovations, Sept. 15, 2016).

Gamma delta T cells have a unique T cell receptor (TCR) that recognizes markers of metabolic stress, which are present on cancer cells. In contrast to alpha beta T cells commonly used for T cell therapies, gamma delta T cells do not require antigen presentation by a major histocompatibility complex (MHC) molecule, creating the potential for fast, potent and off-the-shelf cell therapy products. ...